Hepatitis B and C Surveillance in the WHO European Region

VHPB Budapest, 18-19 March 2010

David Mercer, Communicable Disease Unit, WHO Regional Office for Europe
Hepatitis B Immunization Policy

HepB Implementation
- Universal newborns (28)
- Universal infants (15)
- Universal children/adolescents (3)
- Selective newborns and/or risk groups (7)
Acute Hepatitis B
Reported Cases, European Region

Source: WHO/UNICEF Joint Reporting Form

GAVI Support for HepB vaccine initiated

*Countries reporting
Hepatitis B-Acute (Incidence per 100 000)
WHO European Region, 2000

Incidence per 100 000
- No Data
- < 1
- 1-9.99
- ≥ 10
Hepatitis B-Acute (Incidence per 100 000)
WHO European Region, 2002
Hepatitis B-Acute (Incidence per 100 000) WHO European Region, 2004
Hepatitis B-Acute (Incidence per 100 000)
WHO European Region, 2006

Incidence per 100 000
- No Data
- < 1
- 1-9.99
- ≥ 10
Hepatitis B-Acute (Incidence per 100 000)
WHO European Region, 2008
Acute Hepatitis C
Reported Cases, European Region

Source: WHO/UNICEF Joint Reporting Form
Hepatitis C-Acute (Incidence per 100 000)
WHO European Region, 2000

Incidence per 100 000
- No Data
- < 1
- 1-9.99
- ≥ 10
Hepatitis C-Acute (Incidence per 100 000)
WHO European Region, 2002
Hepatitis C-Acute (Incidence per 100 000)
WHO European Region, 2006

Incidence per 100 000
- No Data
- < 1
- 1-9.99
- ≥ 10
Hepatitis C-Acute (Incidence per 100 000)
WHO European Region, 2008
Hepatitis B-Chronic (Incidence per 100,000)
WHO European Region, 2008

Incidence per 100,000

- No Data
- < 1
- 1-9.99
- ≥ 10
Hepatitis C-Chronic (Incidence per 100 000)
WHO European Region, 2008

Incidence per 100 000
- No Data
- < 1
- 1-9.99
- ≥ 10
Little information on incidence in risk groups
Little information on sub-national incidence
Chronic carriage prevalence unknown
No standard surveillance guidelines or protocols
### Annual Joint Reporting Form Section 3

**WHO/UNICEF Joint Reporting Form on Communicable Diseases for the period January to December 2007**

**Section 3.2 Viral Hepatitis**

<table>
<thead>
<tr>
<th>Disease (ICD-10)</th>
<th>Sex:</th>
<th>0-14 years</th>
<th>15-24 years</th>
<th>25-44 years</th>
<th>50+ years</th>
<th>Unknown</th>
<th>0-14 years</th>
<th>15-24 years</th>
<th>25-44 years</th>
<th>50+ years</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Hepatitis A (E05)</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Hepatitis B (B14)</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Hepatitis C (B17)</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles (E06.0, E06.9)</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Hepatitis E (E07)</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCV Infection (enanthem or rash) (B18.2)</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Surveillance Needs

- Development of surveillance guidelines
- Establishment of expert advisory group
Policy Guidance

- Guidelines
  - Acute infections
  - Chronic carriage
  - Behavioral and risk factor surveillance

- Ethical and practical considerations
  - Linking testing and counseling with other programs (HIV, STI, TB)
  - Treatment and response options
THANK YOU